
FDA Approves Expanded Indication for Abrocitinib to Include Adolescents With Atopic Dermatitis
Expanded indication for abrocitinib (Cibinqo; Pfizer Inc) includes patients 12 to <18 years of age with refractory, moderate-to-severe atopic dermatitis that is not adequately controlled with other systemic medications.



































